Patents by Inventor Dianze Chen

Dianze Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies binding CD24, preparation and use thereof
    Patent number: 11926675
    Abstract: Disclosed is an antibody that specifically binds CD24, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD24 signaling using the antibody or antigen binding portion thereof are also provided.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: March 12, 2024
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
    Inventors: Wenzhi Tian, Song Li, Dianze Chen, Huiqin Guo
  • Recombinant fusion proteins targeting CD47 and CD24, preparation and use thereof
    Patent number: 11891449
    Abstract: The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: February 6, 2024
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
    Inventors: Wenzhi Tian, Song Li, Dianze Chen
  • RECOMBINANT FUSION PROTEINS TARGETING CD47 AND CD38, PREPARATION AND USE THEREOF
    Publication number: 20230110702
    Abstract: The present application provides a recombinant fusion protein containing an anti-CD38 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD38 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD38 using the recombinant fusion protein.
    Type: Application
    Filed: February 4, 2022
    Publication date: April 13, 2023
    Inventors: Wenzhi TIAN, Song LI, Dianze CHEN
  • ANTIBODIES BINDING CD70, PREPARATION AND USE THEREOF
    Publication number: 20230112123
    Abstract: Disclosed is an antibody that specifically binds CD70, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD70 signaling using the antibody or antigen binding portion thereof are also provided.
    Type: Application
    Filed: March 3, 2022
    Publication date: April 13, 2023
    Inventors: Wenzhi TIAN, Song LI, Dianze CHEN, Huiqin GUO
  • ANTIBODIES BINDING CD24, PREPARATION AND USE THEREOF
    Publication number: 20230110607
    Abstract: Disclosed is an antibody that specifically binds CD24, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD24 signaling using the antibody or antigen binding portion thereof are also provided.
    Type: Application
    Filed: March 3, 2022
    Publication date: April 13, 2023
    Inventors: Wenzhi TIAN, Song LI, Dianze CHEN, Huiqin GUO
  • RECOMBINANT FUSION PROTEINS TARGETING CD47 AND CD24, PREPARATION AND USE THEREOF
    Publication number: 20230114491
    Abstract: The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.
    Type: Application
    Filed: December 6, 2021
    Publication date: April 13, 2023
    Inventors: Wenzhi TIAN, Song LI, Dianze CHEN
  • Antibodies binding CD70, preparation and use thereof
    Patent number: 11613584
    Abstract: Disclosed is an antibody that specifically binds CD70, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD70 signaling using the antibody or antigen binding portion thereof are also provided.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: March 28, 2023
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
    Inventors: Wenzhi Tian, Song Li, Dianze Chen, Huiqin Guo